Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 52-Week Low at $142.14

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $142.14 and last traded at $143.25, with a volume of 45496 shares trading hands. The stock had previously closed at $143.80.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Chardan Capital dropped their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Citigroup dropped their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $230.00 to $173.00 in a research report on Friday, February 16th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, April 21st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $215.88.

Alnylam Pharmaceuticals Price Performance

The company’s fifty day moving average price is $150.29 and its 200 day moving average price is $165.97. The company has a market cap of $18.05 billion, a PE ratio of -40.26 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.68) EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ALNY. U.S. Capital Wealth Advisors LLC bought a new position in Alnylam Pharmaceuticals during the third quarter valued at about $10,892,000. Harbor Capital Advisors Inc. grew its position in Alnylam Pharmaceuticals by 6.0% during the third quarter. Harbor Capital Advisors Inc. now owns 2,887 shares of the biopharmaceutical company’s stock valued at $511,000 after buying an additional 163 shares during the period. Commonwealth Equity Services LLC grew its position in Alnylam Pharmaceuticals by 9.1% during the third quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 363 shares during the period. Xponance Inc. grew its position in Alnylam Pharmaceuticals by 0.7% during the third quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock valued at $2,654,000 after buying an additional 109 shares during the period. Finally, Raymond James & Associates grew its position in Alnylam Pharmaceuticals by 5.1% during the third quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company’s stock valued at $2,198,000 after buying an additional 598 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.